Since genetic disruption or pharmacological inhibition of MDM2 led to p53 activation in pancreatic β-cells, we next explored whether the inactivation of p53 could reverse glucose intolerance and defective GSIS in β-MDM2KO mice. The gene discussed is TP53; the disease is Glucose intolerance.